BPC-157 injectable vs oral
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
| Dimension | Injectable | Oral | Source |
|---|---|---|---|
| What is sold | Lyophilized vials (commonly 5 or 10 mg) for reconstitution | Capsules and branded gummies (one 500 ug gummy was the subject of a 2026 single-arm registry study, no published results) | source |
| Stomach stability | Not applicable | BPC-157 is repeatedly described as stable in gastric juice; that is a chemical property, not proof of absorption into blood | source |
| Systemic bioavailability | IM 14-19% (rat), 45-51% (dog); no human measurement | Never measured in any species in a published human-relevant study; permeability uncharacterized | source |
| Routes used in animal efficacy studies | Intraperitoneal dosing dominates the musculoskeletal literature | Drinking-water dosing was reported active in the rat ligament model and across rodent GI models | source |
| Human data by route | Intra-articular knee case series (uncontrolled, n=16 reached); 2-subject IV PK pilot | No published human efficacy or PK data for oral use | source |
| Regulatory notes | FDA's immunogenicity concern is stated for certain routes of administration of compounded BPC-157 | Oral products are equally unapproved; no route changes the FDA status | source |
Neither route has human efficacy or dosing data. This table separates what is documented from what is marketed.